Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Accumulated Expenses (2020 - 2025)

Apellis Pharmaceuticals has reported Accumulated Expenses over the past 6 years, most recently at $7.4 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $7.4 million for Q4 2025, down 94.71% from a year ago — trailing twelve months through Dec 2025 was $7.4 million (down 94.71% YoY), and the annual figure for FY2025 was $7.4 million, down 94.71%.
  • Accumulated Expenses for Q4 2025 was $7.4 million at Apellis Pharmaceuticals, down from $17.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for APLS hit a ceiling of $140.2 million in Q4 2024 and a floor of $6.7 million in Q3 2024.
  • Median Accumulated Expenses over the past 5 years was $56.4 million (2021), compared with a mean of $62.9 million.
  • Biggest five-year swings in Accumulated Expenses: soared 1274.76% in 2024 and later crashed 94.71% in 2025.
  • Apellis Pharmaceuticals' Accumulated Expenses stood at $103.2 million in 2021, then dropped by 7.85% to $95.1 million in 2022, then tumbled by 89.28% to $10.2 million in 2023, then soared by 1274.76% to $140.2 million in 2024, then crashed by 94.71% to $7.4 million in 2025.
  • The last three reported values for Accumulated Expenses were $7.4 million (Q4 2025), $17.5 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.